K63-linked polyubiquitination of LGP2 by Riplet regulates RIG-I-dependent innate immune response

EMBO Rep. 2023 Feb 6;24(2):e54844. doi: 10.15252/embr.202254844. Epub 2022 Dec 14.

Abstract

Type I interferons (IFNs) exhibit strong antiviral activity and induce the expression of antiviral proteins. Since excessive expression of type I IFNs is harmful to the host, their expression should be turned off at the appropriate time. In this study, we find that post-translational modification of LGP2, a member of the RIG-I-like receptor family, modulates antiviral innate immune responses. The LGP2 protein undergoes K63-linked polyubiquitination in response to cytoplasmic double-stranded RNAs or viral infection. Our mass spectrometry analysis reveals the K residues ubiquitinated by the Riplet ubiquitin ligase. LGP2 ubiquitination occurs with a delay compared to RIG-I ubiquitination. Interestingly, ubiquitination-defective LGP2 mutations increase the expression of type I IFN at a late phase, whereas the mutant proteins attenuate other antiviral proteins, such as SP100, PML, and ANKRD1. Our data indicate that delayed polyubiquitination of LGP2 fine-tunes RIG-I-dependent antiviral innate immune responses at a late phase of viral infection.

Keywords: LGP2; innate immunity; ubiquitination; virus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents
  • DEAD Box Protein 58* / genetics
  • DEAD Box Protein 58* / metabolism
  • DEAD-box RNA Helicases* / genetics
  • Humans
  • Immunity, Innate*
  • Interferon Type I* / genetics
  • Ubiquitin / metabolism
  • Ubiquitination
  • Virus Diseases*

Substances

  • Antiviral Agents
  • DEAD Box Protein 58
  • DEAD-box RNA Helicases
  • Interferon Type I
  • Ubiquitin
  • RIGI protein, human
  • DHX58 protein, human

Associated data

  • GEO/GSE176363